Artificial Intelligence In Cancer Diagnostics Market Report 2026

Artificial Intelligence In Cancer Diagnostics Market Overview

• Artificial Intelligence In Cancer Diagnostics market size has reached to $0.52 billion in 2025 • Expected to grow to $2.02 billion in 2030 at a compound annual growth rate (CAGR) of 30.9% • Growth Driver: Revolutionising Cancer Care Artificial Intelligence Emerges As A Key Player In Advancing Cancer Diagnostics • Market Trend: Strategic Collaborations Drive Rapid Deployment Of Ai-Powered Digital Pathology Technologies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Artificial Intelligence In Cancer Diagnostics Market?

Artificial intelligence (AI) in cancer diagnostics refers to the use of advanced computational techniques and algorithms to assist in detecting, diagnosing, and characterizing cancer. Artificial intelligence (AI) is used in cancer diagnostics to improve the speed, accuracy, and efficiency of cancer imaging tests and to detect mammographic abnormalities with comparable accuracy to radiologists. The main components of artificial intelligence in cancer diagnostics are software solutions, hardware, and services. Software solutions refer to customized software applications or systems developed to address specific business needs or solve particular problems and AI-powered software solutions utilize machine learning algorithms and computer vision techniques to analyze medical images, genetic data, and clinical records, enabling accurate cancer detection, classification, and treatment prediction. They are used in breast cancer, lung cancer, prostate cancer, colorectal cancer, brain tumors, and others for applications such as screening and diagnosis, tumor identification, surveillance, and treatment, and are used by hospitals, medical research institutes, diagnostic centers, and contract research organizations.

What Is The Artificial Intelligence In Cancer Diagnostics Market Growth Forecast?

The artificial intelligence in cancer diagnostics market size is expected to see exponential growth in the next few years. It will grow to $2.02 billion in 2030 at a compound annual growth rate (CAGR) of 30.9%. The growth in the forecast period can be attributed to demand for early cancer detection, precision medicine adoption, AI driven diagnostic accuracy improvement, expansion of oncology research funding, integration of genomics and imaging data. Major trends in the forecast period include AI assisted medical imaging analysis, growth of early cancer detection tools, integration of predictive oncology analytics, automation of diagnostic workflows, rising adoption of decision support systems.

Global Artificial Intelligence In Cancer Diagnostics Market Segmentation

1) By Component: Software Solutions, Hardware, Services 2) By Cancer Type: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Other Types 3) By Application: Screening And Diagnosis, Tumor Identification, Surveillance, Treatment 4) By End-User: Hospitals, Medical Research Institute, Diagnostic Centers, Contract Research Organization Subsegments: 1) By Software Solutions: Imaging Analysis Software, Predictive Analytics Software, Decision Support Systems, Data Management Platforms 2) By Hardware: Imaging Devices, Biomarkers Detection Equipment, Computing Infrastructure 3) By Services: Consulting Services, Implementation Services, Maintenance And Support Services, Training Services

What Is The Driver Of The Artificial Intelligence In Cancer Diagnostics Market?

The rising prevalence of cancer is expected to propel the growth of artificial intelligence in the cancer diagnostics market going forward. Cancer refers to uncontrolled cell growth, which impacts various organs and contributes to significant morbidity and mortality worldwide. Artificial intelligence is utilised in cancer diagnostics for accurate and efficient analysis of medical imaging data, aiding in the early detection and precise classification of cancerous lesions. For instance, in January 2025, according to the American Cancer Society, a US-based non-profit organisation, the United States is projected to record 2,041,910 new cancer cases and 618,120 cancer deaths in 2025. Furthermore, in February 2024, according to the World Health Organisation, a Switzerland-based Intergovernmental organisation, in 2022, approximately 20 million new cancer cases were reported, leading to 9.7 million deaths. An estimated 53.5 million individuals were alive within five years after receiving a cancer diagnosis. Therefore, the rising prevalence of cancer is expected to propel the growth of artificial intelligence in the cancer diagnostics market.

Key Players In The Global Artificial Intelligence In Cancer Diagnostics Market

Major companies operating in the artificial intelligence in cancer diagnostics market are Microsoft Corporation; Siemens; Roche Holding AG; Google LCC; International Business Machines Corporation; Thermo Fisher Scientific Inc.; Illumina Inc.; Bio Rad Laboratories Inc.; Flatiron Health; Tempus Labs Inc.; Paige AI Inc.; OncoHealth Corporation; Path AI Inc.; Aidoc; Sophia Genetics SA; Digital Diagnostics Inc.; Prognos Health; Aidence; Kheiron Medical Technologies Limited; Zebra Medical Vision; Niramai; Enlitic Inc.; Therapixel; Medial EarlySign Ltd.; Freenome; SkinVision B.V.

Global Artificial Intelligence In Cancer Diagnostics Market Trends and Insights

Major companies operating in the artificial intelligence in cancer diagnostics market are focusing on strategic collaboration to expedite the deployment of AI-powered digital pathology technologies to aid in cancer diagnosis. Strategic partnerships refer to a process in which companies leverage each other's strengths and resources to achieve mutual benefits and success. For instance, in October 2023, F. Hoffmann-La Roche AG, a Switzerland-based diagnostics and pharmaceutical company, announced a collaboration with Ibex Medical Analytics, an Israel-based medical technology company, and Amazon Web Services, Inc., a US-based comprehensive and broadly adopted cloud, allowing pathology labs to use the navify Digital Pathology software platform to access Ibex's AI-powered decision support capabilities to assist physicians in diagnosing breast and prostate cancer. The cooperation of Ibex Medical Analytics and Roche is generating innovative AI-powered processes to assist pathologists and laboratories in realising the full promise of turning digital. The cloud-based digital pathology and AI solutions from Roche and Ibex are powered by Amazon Web Services (AWS), offering a scalable and sustainable environment for pathology laboratories.

What Are Latest Mergers And Acquisitions In The Artificial Intelligence In Cancer Diagnostics Market?

In July 2025, RadNet Inc., a US-based diagnostic imaging and digital health company, acquired iCAD Inc. for an undisclosed amount. Through this acquisition, RadNet aims to strengthen its cancer screening capabilities by integrating iCAD’s AI-powered breast health technologies for mammography detection, risk assessment, and workflow optimisation. iCAD Inc. is a US-based company that develops artificial intelligence solutions for breast cancer detection, risk evaluation, and screening efficiency.

Regional Insights

North America was the largest region in the artificial intelligence in cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Artificial Intelligence In Cancer Diagnostics Market?

The artificial intelligence (AI) in the cancer diagnostics market consists of revenues earned by entities by providing services such as data analysis, image recognition, personalized medicine, and decision support. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI) in the cancer diagnostics market also includes sales of AI-based diagnostic tools, predictive analytics tools, and a virtual tumor board. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Artificial Intelligence In Cancer Diagnostics Market Report 2026?

The artificial intelligence in cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence in cancer diagnostics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.